Clinical manifestations and management of drug-induced liver diseases

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Drug-induced hepatic injury is of major concern to clinicians, pharmaceutical manufacturers, and regulators. Classic predisposing risk factors to drug-induced liver disease include age, race, and sex. Additional factors of interest are the relationship between the dose of the drug and the extent of metabolism of an individual agent. Recent studies have focused on the role of immune response in determining the onset of drug-induced liver injury. The role of genetics with allelic differences in genes associated with the metabolism and transport of drugs and the susceptibility to liver injury is receiving considerable attention. Important genetic influences on genes in the HLA family are known to affect the likelihood of adverse hepatic reactions with several agents. Awareness of the risks of individual agents remains the most important factor in diagnosis, and withdrawal of the offending agent is the cornerstone of therapy. Recently, considerable attention has been directed toward drugs (e.g., minocycline and nitrofurantoin) that unmask or cause autoimmune hepatitis.

Original languageEnglish (US)
Title of host publicationDrug-Induced Liver Disease
PublisherElsevier Inc.
Pages229-240
Number of pages12
ISBN (Print)9780123878175
DOIs
StatePublished - 2013

Fingerprint

Chemical and Drug Induced Liver Injury
Pharmaceutical Preparations
Liver
Nitrofurantoin
Autoimmune Hepatitis
Minocycline
Wounds and Injuries
Causality
Genes

Keywords

  • Acetaminophen
  • Acute hepatic failure
  • Amoxicillin-clavulanate
  • Autoimmune hepatitis
  • Diclofenac
  • Drug-induced hepatotoxicity
  • Isoniazid
  • Minocycline
  • Statins

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Clinical manifestations and management of drug-induced liver diseases. / Maddrey, Willis C.

Drug-Induced Liver Disease. Elsevier Inc., 2013. p. 229-240.

Research output: Chapter in Book/Report/Conference proceedingChapter

Maddrey, Willis C. / Clinical manifestations and management of drug-induced liver diseases. Drug-Induced Liver Disease. Elsevier Inc., 2013. pp. 229-240
@inbook{9035c8becc2a436b8d8629917507e0bb,
title = "Clinical manifestations and management of drug-induced liver diseases",
abstract = "Drug-induced hepatic injury is of major concern to clinicians, pharmaceutical manufacturers, and regulators. Classic predisposing risk factors to drug-induced liver disease include age, race, and sex. Additional factors of interest are the relationship between the dose of the drug and the extent of metabolism of an individual agent. Recent studies have focused on the role of immune response in determining the onset of drug-induced liver injury. The role of genetics with allelic differences in genes associated with the metabolism and transport of drugs and the susceptibility to liver injury is receiving considerable attention. Important genetic influences on genes in the HLA family are known to affect the likelihood of adverse hepatic reactions with several agents. Awareness of the risks of individual agents remains the most important factor in diagnosis, and withdrawal of the offending agent is the cornerstone of therapy. Recently, considerable attention has been directed toward drugs (e.g., minocycline and nitrofurantoin) that unmask or cause autoimmune hepatitis.",
keywords = "Acetaminophen, Acute hepatic failure, Amoxicillin-clavulanate, Autoimmune hepatitis, Diclofenac, Drug-induced hepatotoxicity, Isoniazid, Minocycline, Statins",
author = "Maddrey, {Willis C.}",
year = "2013",
doi = "10.1016/B978-0-12-387817-5.00014-5",
language = "English (US)",
isbn = "9780123878175",
pages = "229--240",
booktitle = "Drug-Induced Liver Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Clinical manifestations and management of drug-induced liver diseases

AU - Maddrey, Willis C.

PY - 2013

Y1 - 2013

N2 - Drug-induced hepatic injury is of major concern to clinicians, pharmaceutical manufacturers, and regulators. Classic predisposing risk factors to drug-induced liver disease include age, race, and sex. Additional factors of interest are the relationship between the dose of the drug and the extent of metabolism of an individual agent. Recent studies have focused on the role of immune response in determining the onset of drug-induced liver injury. The role of genetics with allelic differences in genes associated with the metabolism and transport of drugs and the susceptibility to liver injury is receiving considerable attention. Important genetic influences on genes in the HLA family are known to affect the likelihood of adverse hepatic reactions with several agents. Awareness of the risks of individual agents remains the most important factor in diagnosis, and withdrawal of the offending agent is the cornerstone of therapy. Recently, considerable attention has been directed toward drugs (e.g., minocycline and nitrofurantoin) that unmask or cause autoimmune hepatitis.

AB - Drug-induced hepatic injury is of major concern to clinicians, pharmaceutical manufacturers, and regulators. Classic predisposing risk factors to drug-induced liver disease include age, race, and sex. Additional factors of interest are the relationship between the dose of the drug and the extent of metabolism of an individual agent. Recent studies have focused on the role of immune response in determining the onset of drug-induced liver injury. The role of genetics with allelic differences in genes associated with the metabolism and transport of drugs and the susceptibility to liver injury is receiving considerable attention. Important genetic influences on genes in the HLA family are known to affect the likelihood of adverse hepatic reactions with several agents. Awareness of the risks of individual agents remains the most important factor in diagnosis, and withdrawal of the offending agent is the cornerstone of therapy. Recently, considerable attention has been directed toward drugs (e.g., minocycline and nitrofurantoin) that unmask or cause autoimmune hepatitis.

KW - Acetaminophen

KW - Acute hepatic failure

KW - Amoxicillin-clavulanate

KW - Autoimmune hepatitis

KW - Diclofenac

KW - Drug-induced hepatotoxicity

KW - Isoniazid

KW - Minocycline

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84882667584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882667584&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-387817-5.00014-5

DO - 10.1016/B978-0-12-387817-5.00014-5

M3 - Chapter

SN - 9780123878175

SP - 229

EP - 240

BT - Drug-Induced Liver Disease

PB - Elsevier Inc.

ER -